Eucapnic hyperpnea from Schiller Healthcare India Pvt. Ltd.

To assess bronchoconstriction and exercise-induced bronchoconstriction (EIB), the eucapnic voluntary hyperpnea (EVH) test emerges as an alternative to conventional methods, such as exercise challenges or methacholine tests. What sets EVH apart is its unique ability to provoke airway responses without the need for medication. Historically, this method has been predominantly employed among elite athletes, and it is widely considered the gold standard for diagnosing EIB within this athletic population. EVH closely simulates the respiratory patterns experienced during exercise. EucapSys is the first commercially available system that makes EVH accessible to a broader range of users, rendering the test more affordable and independent from costly gas mixtures.

EucapSys offers a streamlined one-step protocol for bronchial provocation testing, thereby saving time and making the experience more pleasant for individuals undergoing the test. The system enables drug-free provocation, using dry air, reducing the need for medication. It is designed as a user-friendly stand-alone device, making it accessible and straightforward to implement. With a focus on accuracy, the system demonstrates high specificity, resulting in fewer false positive results. Furthermore, it is an efficient and cost-effective solution for bronchial provocation testing.

The EVH test utilizes a straightforward procedure to assess airway responsiveness. Initially, forced spirometry establishes the baseline for pre-FEV1 (forced expiratory volume in one second). Subsequently, the patient undergoes hyperventilation with a dry gas mixture enriched with 5 percent CO2, delivered at room temperature for roughly 6 minutes via a breathing mask. During this phase, the patient intentionally accelerates their breathing rate, aiming to attain a predetermined individual target, which the EucapSys system continuously monitors. After the provocation phase, post-measurements are performed, and if the post-FEV1 value drops below 10 percent of the baseline FEV1, asthma can be diagnosed.

This device significantly reduces gas-related expenses by an impressive 90 percent, streamlining gas supply logistics, making it an economical choice. Additionally, its operational efficiency is evident as it efficiently utilizes cost-effective cylinders of pressurized air and CO2 to produce the required hypercapnic mixture. This process is further enhanced by innovative patented technology, ensuring the gradual production of a hypercapnic air mixture tailored to individual needs, with the capability to achieve flow rates of up to 200 liters per minute. Moreover, the system dynamically regulates CO2 content at 5 percent, maintaining isocapnia, which is equivalent to 40 mmHg of PetCO2. These features collectively contribute to the effectiveness and cost efficiency of the EucapSys system.

Eucapnic voluntary hyperpnea, powered by the innovative EucapSys system, offers a drug-free and cost-effective approach to bronchial provocation testing, making it accessible to a broader spectrum of individuals. Further, this groundbreaking technology upholds the highest standards of quality and precision in the realm of pulmonary function testing.